Somnomed Limited (AU:SOM) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
SomnoMed Limited has upgraded its FY25 financial guidance, expecting a 5% revenue increase to approximately $105 million and a 40% boost in EBITDA to over $7 million, driven by strong demand and improved production times. The company has also appointed Ye-Fei Guo as the new Chief Financial Officer, bringing over 20 years of finance experience to the role. Investors are optimistic about these developments, which highlight SomnoMed’s strategic growth and leadership in the sleep-related treatment market.
For further insights into AU:SOM stock, check out TipRanks’ Stock Analysis page.
